Search

Your search keyword '"D. Charlety"' showing total 2 results
Start Over Author "D. Charlety" Topic antineoplastic agents
2 results on '"D. Charlety"'

1. Long-Term Survivor with Intrathecal and Intravenous Trastuzumab Treatment in Metastatic Breast Cancer.

Author

Pluchart H, Jacquet E, Charlety D, Allenet B, Bedouch P, and Mousseau M

Subjects
Administration, Intravenous, Adult, Antineoplastic Agents administration & dosage, Antineoplastic Agents pharmacology, Breast Neoplasms mortality, Breast Neoplasms pathology, Female, Humans, Neoplasm Metastasis, Survivors, Trastuzumab administration & dosage, Trastuzumab pharmacology, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Trastuzumab therapeutic use
Abstract

We report the case of a woman with metastatic breast cancer receiving intrathecal trastuzumab (and intravenous trastuzumab for more than 7 years). She was diagnosed in 2001 with a duct invasive breast cancer T3N1M0 HER2 (human epidermal growth factor receptor 2)-positive +++ HR (hormone receptor) -negative. She received chemotherapy and then she had a mastectomy. Several metastases were discovered and treated from 2003 to 2008 with chemotherapy. In March 2010, brain metastases and a leptomeningeal carcinomatosis from her HER2-positive breast cancer appeared. From that moment on she received intravenous trastuzumab (6 mg/kg) every 3 weeks, intrathecal trastuzumab (21 mg) weekly for 16 injections and lapatinib. Intrathecal trastuzumab was stopped because of cerebrospinal fluid (CSF) clearing. Intrathecal trastuzumab was injected again from December 2013 for 14 injections. The relevance of treating leptomeningeal carcinomatosis with intrathecal trastuzumab administration is shown through this case report.

Published
2016
Full Text
View/download PDF

2. Long-Term Survivor with Intrathecal and Intravenous Trastuzumab Treatment in Metastatic Breast Cancer

Author

H. Pluchart, E. Jacquet, Benoît Allenet, D. Charlety, M. Mousseau, Pierrick Bedouch, Pôle Pharmacie [CHU Grenoble Alpes], Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), Techniques pour l'Evaluation et la Modélisation des Actions de la Santé (TIMC-IMAG-ThEMAS), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Techniques pour l'Evaluation et la Modélisation des Actions de la Santé [2016-2019] (TIMC-ThEMAS [2016-2019]), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 [2016-2019] (TIMC [2016-2019]), Institut polytechnique de Grenoble - Grenoble Institute of Technology [2007-2019] (Grenoble INP [2007-2019])-IMAG-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology [2007-2019] (Grenoble INP [2007-2019])-IMAG-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Domaines Océaniques (LDO), Centre National de la Recherche Scientifique (CNRS)-Institut d'écologie et environnement-Observatoire des Sciences de l'Univers-Université de Brest (UBO)-Institut national des sciences de l'Univers (INSU - CNRS), and Institut national des sciences de l'Univers (INSU - CNRS)-Université de Brest (UBO)-Observatoire des Sciences de l'Univers-Institut d'écologie et environnement-Centre National de la Recherche Scientifique (CNRS)

Subjects
Adult, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, [SHS.EDU]Humanities and Social Sciences/Education, [SHS.PSY]Humanities and Social Sciences/Psychology, Antineoplastic Agents, Breast Neoplasms, Lapatinib, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Cerebrospinal fluid, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Trastuzumab, Internal medicine, medicine, Humans, Pharmacology (medical), Survivors, Neoplasm Metastasis, skin and connective tissue diseases, neoplasms, ComputingMilieux_MISCELLANEOUS, Chemotherapy, business.industry, medicine.disease, Metastatic breast cancer, 3. Good health, Hormone receptor, 030220 oncology & carcinogenesis, Administration, Intravenous, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, 030217 neurology & neurosurgery, Mastectomy, medicine.drug
Abstract

We report the case of a woman with metastatic breast cancer receiving intrathecal trastuzumab (and intravenous trastuzumab for more than 7 years). She was diagnosed in 2001 with a duct invasive breast cancer T3N1M0 HER2 (human epidermal growth factor receptor 2)-positive +++ HR (hormone receptor) -negative. She received chemotherapy and then she had a mastectomy. Several metastases were discovered and treated from 2003 to 2008 with chemotherapy. In March 2010, brain metastases and a leptomeningeal carcinomatosis from her HER2-positive breast cancer appeared. From that moment on she received intravenous trastuzumab (6 mg/kg) every 3 weeks, intrathecal trastuzumab (21 mg) weekly for 16 injections and lapatinib. Intrathecal trastuzumab was stopped because of cerebrospinal fluid (CSF) clearing. Intrathecal trastuzumab was injected again from December 2013 for 14 injections. The relevance of treating leptomeningeal carcinomatosis with intrathecal trastuzumab administration is shown through this case report.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results